{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:40:05Z","timestamp":1749310805360,"version":"3.41.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019640","name":"Musashino University","doi-asserted-by":"publisher","award":["O6-172"],"award-info":[{"award-number":["O6-172"]}],"id":[{"id":"10.13039\/100019640","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Diabetic foot lesions are becoming increasingly prevalent due to increases in type 2 diabetes (T2D), aging populations, and atherosclerotic diseases. Individuals with T2D with comorbid lower extremity artery disease (LEAD) are particularly susceptible. Although pharmacological therapies are often combined with risk management strategies, like exercise and smoking cessation, their roles in preventing LEAD progression are unclear. Herein, we investigated factors suppressing LEAD progression in T2D. Using data from the DeSC database, this retrospective cross-sectional study defined severe LEAD as a diagnosis requiring revascularization (Revasc). Logistic regression analysis was used to calculate odds ratios (ORs) for associated factors. The analysis included 243,606 patients with T2D divided into two groups; those with (<jats:italic>n<\/jats:italic>\u2009=\u2009890) and without (<jats:italic>n<\/jats:italic>\u2009=\u2009242,716) Revasc. Subgroup analysis of patients with LEAD (<jats:italic>n<\/jats:italic>\u2009=\u200927,258) with (<jats:italic>n<\/jats:italic>\u2009=\u2009890) and without (<jats:italic>n<\/jats:italic>\u2009=\u200926,368) Revasc was also conducted. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) (OR 0.50), metformin (OR 0.78), and fibrates (OR 0.75) were associated with a significant reduction in severe LEAD in the primary and subgroup analyses. In conclusion, the active use of SGLT2 inhibitors, metformin, and fibrates may help prevent LEAD progression. However, these medications are associated with adverse events, making it essential to manage patients individually to optimize benefits while minimizing risks.<\/jats:p>","DOI":"10.1038\/s41598-025-03797-9","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T03:17:59Z","timestamp":1748920679000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with severe lower extremity artery disease in type 2 diabetes based on a large scale claims database in Japan"],"prefix":"10.1038","volume":"15","author":[{"given":"Takeshi","family":"Horii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ikegami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"3797_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.12.004","volume":"123","author":"M Stolar","year":"2010","unstructured":"Stolar, M. Glycemic control and complications in type 2 diabetes mellitus. Am. J. Med. 123, S3\u2013S11. https:\/\/doi.org\/10.1016\/j.amjmed.2009.12.004 (2010).","journal-title":"Am. J. Med."},{"key":"3797_CR2","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/s1098-3597(07)80018-4","volume":"8","author":"D LeRoith","year":"2007","unstructured":"LeRoith, D. & Rayfield, E. J. The benefits of tight glycemic control in type 2 diabetes mellitus. Clin. Cornerstone. 8, S19\u2013S29. https:\/\/doi.org\/10.1016\/s1098-3597(07)80018-4 (2007).","journal-title":"Clin. Cornerstone"},{"key":"3797_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1586\/14779072.6.3.323","volume":"6","author":"SH Meeuwisse-Pasterkamp","year":"2008","unstructured":"Meeuwisse-Pasterkamp, S. H., van der Klauw, M. M. & Wolffenbuttel, B. H. R. Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Rev. Cardiovasc. Ther. 6, 323\u2013341. https:\/\/doi.org\/10.1586\/14779072.6.3.323 (2008).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"3797_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00125-006-0491-1","volume":"50","author":"L Prompers","year":"2007","unstructured":"Prompers, L. et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe: baseline results from the Eurodiale study. Diabetologia 50, 18\u201325. https:\/\/doi.org\/10.1007\/s00125-006-0491-1 (2007).","journal-title":"Diabetologia"},{"key":"3797_CR5","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song, P. et al. Global, regional, and National prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob. Health. 7, e1020\u2013e1030. https:\/\/doi.org\/10.1016\/S2214-109X(19)30255-4 (2019).","journal-title":"Lancet Glob. Health"},{"key":"3797_CR6","unstructured":"Japan\u2019s Ministry of Health, Labour and Welfare. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/eiyou09\/dl\/01-kekka.pdf"},{"key":"3797_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.2337\/diacare.22.3.382","volume":"22","author":"SD Ramsey","year":"1999","unstructured":"Ramsey, S. D. et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 22, 382\u2013387. https:\/\/doi.org\/10.2337\/diacare.22.3.382 (1999).","journal-title":"Diabetes Care"},{"key":"3797_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2337\/diacare.21.7.1071","volume":"21","author":"CA Abbott","year":"1998","unstructured":"Abbott, C. A., Vileikyte, L., Williamson, S., Carrington, A. L. & Boulton, A. J. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 21, 1071\u20131075. https:\/\/doi.org\/10.2337\/diacare.21.7.1071 (1998).","journal-title":"Diabetes Care"},{"key":"3797_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1046\/j.1464-5491.2002.00698.x","volume":"19","author":"CA Abbott","year":"2002","unstructured":"Abbott, C. A. et al. The North-West diabetes foot care study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet. Med. 19, 377\u2013384. https:\/\/doi.org\/10.1046\/j.1464-5491.2002.00698.x (2002).","journal-title":"Diabet. Med."},{"key":"3797_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-019-0955-5","volume":"18","author":"M Takahara","year":"2019","unstructured":"Takahara, M. et al. Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases. Cardiovasc. Diabetol. 18, 155. https:\/\/doi.org\/10.1186\/s12933-019-0955-5 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"3797_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.diabres.2008.09.008","volume":"82","author":"Y Maeda","year":"2008","unstructured":"Maeda, Y. et al. High prevalence of peripheral arterial disease diagnosed by low ankle-brachial index in Japanese patients with diabetes: the Kyushu prevention study for atherosclerosis. Diabetes Res. Clin. Pract. 82, 378\u2013382. https:\/\/doi.org\/10.1016\/j.diabres.2008.09.008 (2008).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"3797_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2014.03.018","volume":"234","author":"C Natsuaki","year":"2014","unstructured":"Natsuaki, C. et al. Association of borderline ankle-brachial index with mortality and the incidence of peripheral artery disease in diabetic patients. Atherosclerosis 234, 360\u2013365. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.03.018 (2014).","journal-title":"Atherosclerosis"},{"key":"3797_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/2047487312452968","volume":"21","author":"LH Eraso","year":"2014","unstructured":"Eraso, L. H. et al. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. Eur. J. Prev. Cardiol. 21, 704\u2013711. https:\/\/doi.org\/10.1177\/2047487312452968 (2014).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"3797_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","volume":"51","author":"B Sigvant","year":"2016","unstructured":"Sigvant, B., Lundin, F. & Wahlberg, E. The risk of disease progression in peripheral arterial disease is higher than expected: A meta-analysis of mortality and disease progression in peripheral arterial disease. Eur. J. Vasc Endovasc. Surg. 51, 395\u2013403. https:\/\/doi.org\/10.1016\/j.ejvs.2015.10.022 (2016).","journal-title":"Eur. J. Vasc Endovasc. Surg."},{"key":"3797_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.jvs.2011.10.128","volume":"55","author":"JJ Siracuse","year":"2012","unstructured":"Siracuse, J. J. et al. Results for primary bypass versus primary angioplasty\/stent for intermittent claudication due to superficial femoral artery occlusive disease. J. Vasc Surg. 55, 1001\u20131007. https:\/\/doi.org\/10.1016\/j.jvs.2011.10.128 (2012).","journal-title":"J. Vasc Surg."},{"key":"3797_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1526602820962972","volume":"28","author":"S Giannopoulos","year":"2021","unstructured":"Giannopoulos, S. et al. Three-year outcomes from the LIBERTY 360 study of endovascular interventions for peripheral artery disease stratified by Rutherford category. J. Endovasc. Ther. 28, 262\u2013274. https:\/\/doi.org\/10.1177\/1526602820962972 (2021).","journal-title":"J. Endovasc. Ther."},{"key":"3797_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ejvs.2017.07.005","volume":"54","author":"E Baubeta Fridh","year":"2017","unstructured":"Baubeta Fridh, E. et al. Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population-based study. Eur. J. Vasc Endovasc. Surg. 54, 480\u2013486. https:\/\/doi.org\/10.1016\/j.ejvs.2017.07.005 (2017).","journal-title":"Eur. J. Vasc Endovasc. Surg."},{"key":"3797_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1253\/circj.cj-10-0077","volume":"74","author":"Y Soga","year":"2010","unstructured":"Soga, Y. et al. Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease. Circ. J. 74, 1689\u20131695. https:\/\/doi.org\/10.1253\/circj.cj-10-0077 (2010).","journal-title":"Circ. J."},{"key":"3797_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.avsg.2017.04.021","volume":"44","author":"JT Saraidaridis","year":"2017","unstructured":"Saraidaridis, J. T. et al. The natural history and outcomes of endovascular therapy for claudication. Ann. Vasc. Surg. 44, 34\u201340. https:\/\/doi.org\/10.1016\/j.avsg.2017.04.021 (2017).","journal-title":"Ann. Vasc. Surg."},{"key":"3797_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.apmr.2004.06.072","volume":"86","author":"TR Dillingham","year":"2005","unstructured":"Dillingham, T. R., Pezzin, L. E. & Shore, A. D. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. Arch. Phys. Med. Rehabil. 86, 480\u2013486. https:\/\/doi.org\/10.1016\/j.apmr.2004.06.072 (2005).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"3797_CR21","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.avsg.2012.02.011","volume":"26","author":"Y Kono","year":"2012","unstructured":"Kono, Y. & Muder, R. R. Identifying the incidence of and risk factors for reamputation among patients who underwent foot amputation. Ann. Vasc. Surg. 26, 1120\u20131126. https:\/\/doi.org\/10.1016\/j.avsg.2012.02.011 (2012).","journal-title":"Ann. Vasc. Surg."},{"key":"3797_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jvs.2015.02.021","volume":"62","author":"RJ Beaulieu","year":"2015","unstructured":"Beaulieu, R. J. et al. Rates and predictors of readmission after minor lower extremity amputations. J. Vasc. Surg. 62, 101\u2013105. https:\/\/doi.org\/10.1016\/j.jvs.2015.02.021 (2015).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1479164115579005","volume":"12","author":"M Hoffmann","year":"2015","unstructured":"Hoffmann, M. et al. Survival of diabetes patients with major amputation is comparable to malignant disease. Diabetes Vasc. Dis. Res. 12, 265\u2013271. https:\/\/doi.org\/10.1177\/1479164115579005 (2015).","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"3797_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","volume":"295","author":"DL Bhatt","year":"2006","unstructured":"Bhatt, D. L. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295, 180\u2013189. https:\/\/doi.org\/10.1001\/jama.295.2.180 (2006).","journal-title":"JAMA"},{"key":"3797_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","volume":"124","author":"RL Pande","year":"2011","unstructured":"Pande, R. L. et al. Secondary prevention and mortality in peripheral artery disease: National health and nutrition examination study, 1999 to 2004. Circulation 124, 17\u201323. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.003954 (2011).","journal-title":"Circulation"},{"key":"3797_CR26","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","volume":"51","author":"GMJM Welten","year":"2008","unstructured":"Welten, G. M. J. M. et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J. Am. Coll. Cardiol. 51, 1588\u20131596. https:\/\/doi.org\/10.1016\/j.jacc.2007.11.077 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3797_CR27","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/eurheartj\/ehu071","volume":"35","author":"A Gallino","year":"2014","unstructured":"Gallino, A. et al. Non-coronary atherosclerosis. Eur. Heart J. 35, 1112\u20131119. https:\/\/doi.org\/10.1093\/eurheartj\/ehu071 (2014).","journal-title":"Eur. Heart J."},{"key":"3797_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/obr.12755","volume":"19","author":"PC Lee","year":"2018","unstructured":"Lee, P. C., Ganguly, S. & Goh, S. Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes. Rev. 19, 1630\u20131641. https:\/\/doi.org\/10.1111\/obr.12755 (2018).","journal-title":"Obes. Rev."},{"key":"3797_CR29","doi-asserted-by":"publisher","first-page":"102272","DOI":"10.1016\/j.coph.2022.102272","volume":"66","author":"M Chiriac\u00f2","year":"2022","unstructured":"Chiriac\u00f2, M., Tric\u00f2, D. & Solini, A. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. Curr. Opin. Pharmacol. 66, 102272. https:\/\/doi.org\/10.1016\/j.coph.2022.102272 (2022).","journal-title":"Curr. Opin. Pharmacol."},{"key":"3797_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MOL.0000000000000751","volume":"32","author":"J Lazarte","year":"2021","unstructured":"Lazarte, J., Kanagalingam, T. & Hegele, R. A. Lipid effects of sodium-glucose cotransporter 2 inhibitors. Curr. Opin. Lipidol. 32, 183\u2013190. https:\/\/doi.org\/10.1097\/MOL.0000000000000751 (2021).","journal-title":"Curr. Opin. Lipidol."},{"key":"3797_CR31","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/dom.12697","volume":"18","author":"E Bahne","year":"2016","unstructured":"Bahne, E. et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of Metformin. Diabetes Obes. Metab. 18, 955\u2013961. https:\/\/doi.org\/10.1111\/dom.12697 (2016).","journal-title":"Diabetes Obes. Metab."},{"key":"3797_CR32","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.52711\/0974-360X.2021.01070","volume":"14","author":"M Avijit","year":"2021","unstructured":"Avijit, M. & Ashini, S. A review on metformin: clinical significance and side effects. Res. J. Pharm. Technol. 14, 6179\u20136186. https:\/\/doi.org\/10.52711\/0974-360X.2021.01070 (2021).","journal-title":"Res. J. Pharm. Technol."},{"key":"3797_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1517\/13543784.2012.696609","volume":"21","author":"IP Salt","year":"2012","unstructured":"Salt, I. P. & Palmer, T. M. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin. Investig. Drugs. 21, 1155\u20131167. https:\/\/doi.org\/10.1517\/13543784.2012.696609 (2012).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"3797_CR34","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1161\/CIRCULATIONAHA.107.744490","volume":"117","author":"Z Xie","year":"2011","unstructured":"Xie, Z., Dong, Y., Scholz, R., Neumann, D. & Zou, M. H. Phosphorylation of LKB1 at Serine 428 by protein kinase C-\u03b6 is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 117, 952\u2013962. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.744490 (2011).","journal-title":"Circulation"},{"key":"3797_CR35","doi-asserted-by":"publisher","first-page":"173484","DOI":"10.1016\/j.ejphar.2020.173484","volume":"888","author":"R Ding","year":"2020","unstructured":"Ding, R., Wu, W., Sun, Z. & Li, Z. AMP-activated protein kinase: an attractive therapeutic target for ischemia-reperfusion injury. Eur. J. Pharmacol. 888, 173484. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173484 (2020).","journal-title":"Eur. J. Pharmacol."},{"key":"3797_CR36","doi-asserted-by":"publisher","unstructured":"Bakhshaei, S. et al. Impact of Metformin on hypertension: current knowledge. J. Ren. Endocrinol. 8 https:\/\/doi.org\/10.34172\/jre.2022.25067 (2022).","DOI":"10.34172\/jre.2022.25067"},{"key":"3797_CR37","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1097\/HJH.0b013e328353e249","volume":"30","author":"H He","year":"2012","unstructured":"He, H. et al. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. J. Hypertens. 30, 1430\u20131439. https:\/\/doi.org\/10.1097\/HJH.0b013e328353e249 (2012).","journal-title":"J. Hypertens."},{"key":"3797_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/s41440-019-0212-z","volume":"42","author":"C Chen","year":"2019","unstructured":"Chen, C. et al. Metformin prevents vascular damage in hypertension through the AMPK\/ER stress pathway. Hypertens. Res. 42, 960\u2013969. https:\/\/doi.org\/10.1038\/s41440-019-0212-z (2019).","journal-title":"Hypertens. Res."},{"key":"3797_CR39","doi-asserted-by":"publisher","unstructured":"Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366, 1849\u20131861. https:\/\/doi.org\/10.1016\/S0140-6736(05)67667-2 (2005). (Erratum in: Lancet 368, 1420 (2006). Doi: 10.1016\/S0140-6736(06)69595-0)","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"3797_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","volume":"205","author":"JC Fruchart","year":"2009","unstructured":"Fruchart, J. C. Peroxisome proliferator-activated receptor-alpha (PPAR\u03b1): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205, 1\u20138. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.03.008 (2009).","journal-title":"Atherosclerosis"},{"key":"3797_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2337\/dc17-1589","volume":"41","author":"E Araki","year":"2018","unstructured":"Araki, E. et al. Effects of pemafibrate, a novel selective PPAR\u03b1 modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 41, 538\u2013546. https:\/\/doi.org\/10.2337\/dc17-1589 (2018).","journal-title":"Diabetes Care"},{"key":"3797_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"S Ishibashi","year":"2016","unstructured":"Ishibashi, S. et al. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis 249, 36\u201343. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.029 (2016).","journal-title":"Atherosclerosis"},{"key":"3797_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","volume":"141","author":"E Selvin","year":"2004","unstructured":"Selvin, E. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 141, 421\u2013431. https:\/\/doi.org\/10.7326\/0003-4819-141-6-200409210-00007 (2004).","journal-title":"Ann. Intern. Med."},{"key":"3797_CR44","doi-asserted-by":"publisher","first-page":"d4169","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon, R. et al. Effect of intensive glucose Lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343, d4169. https:\/\/doi.org\/10.1136\/bmj.d4169 (2011).","journal-title":"BMJ"},{"issue":"Suppl","key":"3797_CR45","doi-asserted-by":"publisher","first-page":"22S","DOI":"10.1016\/j.jvs.2015.10.005","volume":"63","author":"R Hasan","year":"2016","unstructured":"Hasan, R. et al. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. J. Vasc. Surg. 63 (Suppl), 22S\u201328Se1. https:\/\/doi.org\/10.1016\/j.jvs.2015.10.005 (2016).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR46","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/0003319717736627","volume":"69","author":"K Senda","year":"2018","unstructured":"Senda, K. et al. Predictive value of underweight status for patients with peripheral artery disease with claudication. Angiology 69, 513\u2013522. https:\/\/doi.org\/10.1177\/0003319717736627 (2018).","journal-title":"Angiology"},{"issue":"Suppl","key":"3797_CR47","doi-asserted-by":"publisher","first-page":"52S","DOI":"10.1016\/j.jvs.2010.01.077","volume":"51","author":"AW Bradbury","year":"2010","unstructured":"Bradbury, A. W. et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making. J. Vasc. Surg. 51 (Suppl), 52S\u201368S. https:\/\/doi.org\/10.1016\/j.jvs.2010.01.077 (2010).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR48","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jvs.2014.02.059","volume":"60","author":"T Shiraki","year":"2014","unstructured":"Shiraki, T. et al. Predictive scoring model of mortality after surgical or endovascular revascularization in patients with critical limb ischemia. J. Vasc. Surg. 60, 383\u2013389. https:\/\/doi.org\/10.1016\/j.jvs.2014.02.059 (2014).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR49","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jcin.2014.06.018","volume":"7","author":"Y Soga","year":"2014","unstructured":"Soga, Y. et al. Two-year life expectancy in patients with critical limb ischemia. JACC Cardiovasc. Interv. 7, 1444\u20131449. https:\/\/doi.org\/10.1016\/j.jcin.2014.06.018 (2014).","journal-title":"JACC Cardiovasc. Interv."},{"key":"3797_CR50","doi-asserted-by":"publisher","first-page":"e008015","DOI":"10.1161\/CIRCINTERVENTIONS.119.008015","volume":"12","author":"N Azuma","year":"2019","unstructured":"Azuma, N. et al. Predictive model for mortality risk including the wound, ischemia, foot infection classification in patients undergoing revascularization for critical limb ischemia. Circ. Cardiovasc. Interv. 12, e008015. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008015 (2019).","journal-title":"Circ. Cardiovasc. Interv."},{"key":"3797_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ejvs.2020.11.036","volume":"61","author":"T Shiraki","year":"2021","unstructured":"Shiraki, T. et al. SPINACH study investigators. Baseline and updated information on nutritional status in patients with chronic limb-threatening ischaemia undergoing revascularisation. Eur. J. Vasc. Endovasc. Surg. 61, 467\u2013472 (2021).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"3797_CR52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.5551\/jat.57711","volume":"28","author":"Y Hata","year":"2021","unstructured":"Hata, Y. et al. Risk stratification for 2-year mortality in patients with chronic limb-threatening ischemia undergoing endovascular therapy. J. Atheroscler. Thromb. 28, 477\u2013482. https:\/\/doi.org\/10.5551\/jat.57711 (2021).","journal-title":"J. Atheroscler. Thromb."},{"key":"3797_CR53","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jvs.2012.09.083","volume":"57","author":"AJ Meltzer","year":"2013","unstructured":"Meltzer, A. J. et al. The comprehensive risk assessment for bypass (CRAB) facilitates efficient perioperative risk assessment for patients with critical limb ischemia. J. Vasc. Surg. 57, 1186\u20131195. https:\/\/doi.org\/10.1016\/j.jvs.2012.09.083 (2013).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR54","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jvs.2015.09.051","volume":"63","author":"JP Simons","year":"2016","unstructured":"Simons, J. P. et al. A comparative evaluation of risk-adjustment models for benchmarking amputation-free survival after lower extremity bypass. J. Vasc. Surg. 63, 990\u2013997. https:\/\/doi.org\/10.1016\/j.jvs.2015.09.051 (2016).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvs.2012.04.074","volume":"57","author":"PW Moxey","year":"2013","unstructured":"Moxey, P. W. et al. The BASIL survival prediction model in patients with peripheral arterial disease undergoing revascularization in a university hospital setting and comparison with the FINNVASC and modified PREVENT scores. J. Vasc. Surg. 57, 1\u20137. https:\/\/doi.org\/10.1016\/j.jvs.2012.04.074 (2013).","journal-title":"J. Vasc. Surg."},{"issue":"Suppl","key":"3797_CR56","doi-asserted-by":"publisher","first-page":"137S","DOI":"10.1016\/j.jvs.2018.08.169","volume":"69","author":"J P Simons","year":"2019","unstructured":"P Simons, J. et al. Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. J. Vasc. Surg. 69 (Suppl), 137S\u2013151Se3. https:\/\/doi.org\/10.1016\/j.jvs.2018.08.169 (2019).","journal-title":"J. Vasc. Surg."},{"key":"3797_CR57","doi-asserted-by":"publisher","first-page":"e006778","DOI":"10.1161\/CIRCINTERVENTIONS.118.006778","volume":"11","author":"Y Takeji","year":"2018","unstructured":"Takeji, Y. et al. Impact of frailty on clinical outcomes in patients with critical limb ischemia. Circ. Cardiovasc. Interv. 11, e006778. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.118.006778 (2018).","journal-title":"Circ. Cardiovasc. Interv"},{"key":"3797_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1053\/j.semvascsurg.2015.10.003","volume":"28","author":"LW Kraiss","year":"2015","unstructured":"Kraiss, L. W. et al. Frailty assessment in vascular surgery and its utility in preoperative decision making. Semin Vasc. Surg. 28, 141\u2013147. https:\/\/doi.org\/10.1053\/j.semvascsurg.2015.10.003 (2015).","journal-title":"Semin Vasc. Surg."},{"key":"3797_CR59","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1161\/01.cir.0000049640.46039.52","volume":"107","author":"PS Mehler","year":"2003","unstructured":"Mehler, P. S. et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 107, 753\u2013756. https:\/\/doi.org\/10.1161\/01.cir.0000049640.46039.52 (2003).","journal-title":"Circulation"},{"key":"3797_CR60","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.118.033348","volume":"138","author":"NK Itoga","year":"2018","unstructured":"Itoga, N. K. et al. Association of blood pressure measurements with peripheral artery disease events. Circulation 138, 1805\u20131814. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.033348 (2018).","journal-title":"Circulation"},{"key":"3797_CR61","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jacc.2019.07.037","volume":"74","author":"F Emanuelsson","year":"2019","unstructured":"Emanuelsson, F. et al. Impact of LDL cholesterol on microvascular versus macrovascular disease: a Mendelian randomization study. J. Am. Coll. Cardiol. 74, 1465\u20131476. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.037 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3797_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2004.05.028","volume":"177","author":"T Fujiwara","year":"2004","unstructured":"Fujiwara, T. et al. Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. Atherosclerosis 177, 83\u201388. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.05.028 (2004).","journal-title":"Atherosclerosis"},{"key":"3797_CR63","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5551\/jat.3731","volume":"17","author":"H Ohnishi","year":"2010","unstructured":"Ohnishi, H. et al. Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis: the Kyushu and Okinawa population study (KOPS). J. Atheroscler. Thromb. 17, 751\u2013758. https:\/\/doi.org\/10.5551\/jat.3731 (2010).","journal-title":"J. Atheroscler. Thromb."},{"key":"3797_CR64","first-page":"347","volume":"102","author":"RC Oh","year":"2020","unstructured":"Oh, R. C. et al. Management of hypertriglyceridemia: common questions and answers. Am. Fam. Phys. 102, 347\u2013354 (2020).","journal-title":"Am. Fam. Phys."},{"key":"3797_CR65","doi-asserted-by":"publisher","unstructured":"Eraso, L. H. et al. Peripheral arterial dis ease, prevalence and cumulative risk factor profile analysis. Eur. J. Prev. Cardiol.. 21: 704\u2013711. https:\/\/doi.org\/10.1177\/2047487312452968 (2014). (Epub 2012 Jun 27)","DOI":"10.1177\/2047487312452968"},{"key":"3797_CR66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","volume":"51","author":"B Sigvant","year":"2016","unstructured":"Sigvant, B., Lundin, F. & Wahlberg, E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral Arte Rial disease. Eur. J. Vasc. Endovasc. Surg. 51, 395\u2013403  (2016). https:\/\/doi.org\/10.1016\/j.ejvs.2015.10.022 (Epub 2016 Jan 6).","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"3797_CR67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jama.295.2.180","volume":"295","author":"DL Bhatt","year":"2006","unstructured":"Bhatt, D. L. et al. REACH registry investiga Tors. International prevalence, recognition, and treatment of cardio vascular risk factors in outpatients with atherothrombosis. JAMA 295, 180\u2013189  (2006). https:\/\/doi.org\/10.1001\/jama.295.2.180.","journal-title":"JAMA"},{"key":"3797_CR68","doi-asserted-by":"publisher","unstructured":"Pande, R. L. et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation   124, 17\u201323 (2011). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.003954 (Epub 2011 Jun 20).","DOI":"10.1161\/CIRCULATIONAHA.110.003954"},{"key":"3797_CR69","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","volume":"51","author":"GM Welten","year":"2008","unstructured":"Welten, G. M. et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J. Am. Coll. Cardiol. 51, 1588\u20131596 (2008). https:\/\/doi.org\/10.1016\/j.jacc.2007.11.077.","journal-title":"J. Am. Coll. Cardiol."},{"key":"3797_CR70","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1093\/eurheartj\/ehu071","volume":"35","author":"A Gallino","year":"2014","unstructured":"Gallino, A. et al. Non-coronary atherosclero Sis. Eur. Heart J. 35, 1112\u20131119  (2014). https:\/\/doi.org\/10.1093\/eurheartj\/ehu071. Epub 2014 Mar 3.","journal-title":"Eur. Heart J."},{"key":"3797_CR71","first-page":"e45","volume":"25","author":"FS Wicke","year":"2019","unstructured":"Wicke, F. S. et al. Performance of the adapted diabetes complications severity index translated to ICD-10. Am. J. Manag Care. 25, e45\u2013e49 (2019).","journal-title":"Am. J. Manag. Care"},{"key":"3797_CR72","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/1753-0407.12613","volume":"10","author":"K Pantalone","year":"2018","unstructured":"Pantalone, K. et al. Effect of glycemic control on the diabetes complications severity index score and development of complications in people with newly diagnosed type 2 diabetes. J. Diabetes. 10, 192\u2013199 (2018).","journal-title":"J. Diabetes"},{"key":"3797_CR73","first-page":"25","volume":"25","author":"JCS\/JSVS","year":"2022","unstructured":"JCS\/JSVS. Guideline on the management of peripheral arterial disease. Jpn. Circ. J. 25, 25\u201383 (2022).","journal-title":"Jpn. Circ. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03797-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:01:53Z","timestamp":1749308513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3797"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03797-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19358"}}